STREAGER: Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
Study Details
Study Description
Brief Summary
A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non-severe fibrosis
The primary objectives of this study are as follows:
-
To evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
-
To evaluate the safety and tolerability of EBV/GZR treatment
The secondary objectives of this study are as follows:
-
To determine the proportion of subjects who attain SVR at 4 and 24 weeks after cessation of treatment (SVR4 and SVR24)
-
To evaluate the proportion of subjects with virologic failure
-
To evaluate the kinetics of circulating HCV RNA during treatment and after cessation of treatment.
-
To evaluate the emergence of viral resistance to EBV/GZR during treatment and after cessation of treatment
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
One hundred twenty treatment-naïve subjects with chronic HCV GT1b infection without cirrhosis will be enrolled.
There will be one treatment group with EBV/GZR (50/100 mg) once daily without regards to food for 8 weeks.
EBV/GZR is manufactured as a 50/100 mg tablet for oral administration. Subjects will take 1 tablet daily.
Screening assessments will be completed within 28 days of the Day 1 visit. The screening window can be extended to 42 days for subjects requiring a liver biopsy, or extenuating circumstances.
All subjects will complete the following study visits: Screening, Day 1, and on-treatment visits at the end of week 2, week 4 and week 8.
Post-treatment visits will occur at Weeks 4, 12, and 24 after last dose of study drug. All subjects will complete the posttreatment Week 4 and 12 visits. Subjects who achieve SVR12 (HCV RNA < LLOQ at posttreatment Week12) will complete the posttreatment Week 24 visit.
Screening assessments will include physical examination, medical history, height, weight, vital signs, adverse events related to screening procedures, concomitant medications, safety laboratory tests (including hematology, chemistry, and coagulation), HCV RNA, serology (HCV, HBV), serology and/or antigen testing for HIV, HCV genotyping, hemoglobin A1c (HbA1c), assessment of the absence of cirrhosis or severe fibrosis (including Fibrotest® and Fibroscan®), serum β-human chorionic gonadotropin (β-hCG) (females of child-bearing potential only), urinalysis.
On-treatment assessments include adverse events (AEs), concomitant medications, study medication dispensation and pill count, physical examination, weight, vital signs, safety laboratory tests, HCV RNA, and urine pregnancy tests (females of child bearing potential only).
Post-treatment assessments include AEs, concomitant medications, vital signs, safety laboratory tests (including hematology, chemistry, and coagulation), HCV RNA, and urine pregnancy tests (females of child-bearing potential only).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Elbasvir/Grazoprevir evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12). |
Drug: Elbasvir/Grazoprevir Fixed Dose Combination
Evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
|
Outcome Measures
Primary Outcome Measures
- Evaluation of the Efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve as Measured by the Proportion of Subjects With Sustained Viral Response 12 Weeks After Cessation of Treatment (SVR 12). [at 12 weeks post-treatment]
Blood samples for HCV RNA determination were collected 12 weeks after cessation of treatment and analysed by local laboratories tests
Secondary Outcome Measures
- Evaluation of the Safety and Tolerability of EBV/GZR Treatment by Number of Patients With Treatment-related Asthenia Reported [Between the first day of treatment to 24 weeks after the end of treatment, an average of 32 weeks]
Asthenia was defined by abnormal physical weakness or lack of energy. Asthenia was monitored throughout the study and up to 24 weeks after planned end of treatment. An investigator who is a qualified physician evaluated all adverse events, causality and severity. Only grade 1 or 2 were reported. No grade 3. Grade was evaluated with table 9 of protocol.
- Evaluation of the Safety and Tolerability of EBV/GZR Treatment by Number of Patients With Treatment-related Headache Reported [between the first day of treatment to 24 weeks after the end of treatment, an average of 32 weeks]
Headache is defined by pain felt in the cranial box. Headache was monitored throughout the study and up to 24 weeks after planned end of treatment. An investigator who is a qualified physician evaluated all adverse events, causality and severity. Only grade 1 or 2 were reported. No grade 3. grade was evaluated with table 9 of protocol.
- Evaluation of the Safety and Tolerability of EBV/GZR Treatment by Number of Patients With Treatment-related Digestive Disorders Reported [Between the first day of treatment to 24 weeks after the end of treatment, an average of 32 weeks]
Digestive disorders is defined by an acceleration, a slowing down or a disturbance of the intestinal transit with or without pain. Digestive disorders were monitored throughout the study and up to 24 weeks after planned end of treatment. An investigator who is a qualified physician evaluated digestive disorders causality and severity. Only grade 1 or 2 were reported. No grade 3. Grade was evaluated with table 9 of protocol.
- Percentage of Subjects Who Attain SVR at 4 Weeks After Cessation of Treatment (SVR4) [at 4 weeks after cessation of treatment]
blood samples were collected at 4 weeks after cessation of treatment and HCV RNA was measured using local laboratories tests
- Percentage of Subjects Who Attain SVR 24 Weeks After Cessation of Treatment (SVR 24) [at 24 weeks after cessation of treatment]
blood samples were collected at 24 weeks after cessation of treatment and HCV RNA was measured using local laboratories tests
- Percentage of Subjects With Virologic Failure [at 12 weeks after cessation of treatment]
patient with HCV RNA > low limit of quantification in two different consecutive blood samples were considered as relapser
- Evaluation of the Emergence of Viral Resistance to EBV/GZR at 24 Weeks After Cessation of Treatment [at 24 weeks after end of treatment]
Patients with HCV RNA> low limit of quantification in two consecutive blood samples were considered as relapsers.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Willing and able to provide written informed consent
-
Male or female, age ≥ 18 years
-
Body Mass Index (BMI) ≥ 18 kg/m2
-
HCV RNA ≥ 100 000 IU/mL at Screening
-
Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy, only genotype 1b virus. (Positive for anti HCV antibody, HCV RNA, or an HCV genotype)
-
Treatment-naïve with no prior exposure to any IFN, RBV, or approved or experimental HCV-specific DAA
-
Non severe fibrosis (F<2) according to combination of this two tests :
Fibroscan lower than 9.5kPa and Fibrotest lower than 0.59
-
Females of childbearing potential (as defined in protocol Appendix 4) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 prior to enrollment
-
Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use 2 effective method(s) of contraception from at least two weeks prior to Day 1 through 14 days after the last dose of study drugs.
-
If acceptable by local regulatory agencies, methods of birth control allowed in the study are: intrauterine device (IUD), diaphragm with spermicide, hormonal contraceptives (e.g., birth control pills, transdermal patch, or injectables), contraceptive sponge, female condom, male condom with spermicide or vasectomy.
-
Note: Periodic abstinence (e.g., abstinence only on certain calendar days, abstinence only during ovulation period, use of symptothermal methods, use of post-ovulation methods and withdrawal) are not acceptable methods of contraception.
-
A female subject who is not of reproductive potential is eligible without requiring the use of contraception. A female subjects who is not of reproductive potentials is defined as one who has either 1) reached natural menopause (defined as 12 months with no menses without an alternative medical cause), 2) 6 weeks post surgical bilateral oophorectomy with or without hysterectomy, or 3) bilateral tubal ligation.
-
A male subject who is not of reproductive potential is eligible without requiring the use of contraception. A male subject who is not of reproductive potential is defined as: one who has undergone a successful vasectomy. A successful vasectomy is defined as: (1) microscopic documentation of azoospermia, or (2) a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post vasectomy.
-
Lactating females must agree to discontinue nursing before starting study drug
-
Subject must be of generally good health, with the exception of chronic HCV infection, as determined by the Investigator
-
Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments
Exclusion Criteria:
-
Is under the age of legal consent, is mentally or legally incapacitated, has significant emotional problems at the time of pre-study screening visit or expected during the conduct of the study or has a history of a clinically significant psychiatric disorder which, in the opinion of the investigator, would interfere with the study procedures.
-
Current or prior history of any of the following:
-
Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically significant illness (other than HCV) are also excluded
-
Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug
-
Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy
-
History of decompensation (e.g., clinical ascites, encephalopathy, and/or variceal hemorrhage)
-
Solid organ transplantation (including hematopoietic stem cell transplants) other than kidney, cornea and hair.
-
Significant cardiac disease
-
Unstable psychiatric condition including hospitalization, suicidal attempt, and/or a period of disability as a result of their psychiatric illness within 2 years prior to Screening
-
Malignancy within the 5 years prior to Screening, with the exception of specific cancers that have been cured by surgical resection (e.g., basal cell skin cancer, etc.). Subjects under evaluation for possible malignancy are not eligible
-
Significant drug allergy (e.g., hepatotoxicity)
-
Subject has the following laboratory parameters at Screening:
-
ALT > 10 x the upper limit of normal (ULN)
-
AST > 10 x ULN
-
Direct bilirubin > 1.5 x ULN
-
Platelets < 75,000/μL
-
HbA1c > 8.5%
-
Creatinine clearance < 50 mL/min as calculated by the Cockcroft-Gault equation
-
Hemoglobin < 10 g/dL
-
Albumin < 3 g/dL
-
INR > 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regime affecting INR
-
Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis)
-
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
-
Clinically-relevant alcohol or drug abuse within 12 months of Screening.
-
Alcohol, intravenous drugs, inhalational (not including marijuana), psychotropic, narcotics, cocaine use, prescription or over-the-counter drugs: within 1 year of the screening visit, or if shorter, is judged by investigator to be capable of complying with study procedures
-
receiving opiate agonist substitution therapy within 1 year of screening visit, or if shorter, is judged by investigator to be capable of complying with study procedures
-
history of marijuana use if deemed excessive by a physician investigator or interferes with the subject's daily function. If subject's marijuana use is not deemed excessive and does not interfere with daily function, subject must agree to discontinue any current use of recreational marijuana prior to entry into trial and throughout the trial period
-
A positive drug screen will exclude subjects unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by the investigator
-
Use of any prohibited concomitant medication listed in Section 5.5 of this protocol within 2 weeks prior to day 1.
-
Known hypersensitivity to the study drug, the metabolites, or formulation excipient
-
is currently participating or has participated in a study with an investigational compound within 30 days of signing informed consent and is not willing to refrain from participating in another study. Collection of additional blood, urine, or tissue samples or additional data, beyond that specified in this protocol, is prohibited (other than that related to subject's medical care).
-
(female) is pregnant, lactating, expecting to conceive or donate eggs, or is of childbearing potential and unwilling to commit to two methods of birth control throughout treatment and after the completion of all treatment (see Inclusion Criteria); or male subject is planning to impregnate or provide sperm donation or has a female sexual partner of childbearing potential and is unwilling to commit to using a two methods of birth control throughout treatment and after the completion of all treatment (see Inclusion Criteria).
-
had a life-threatening SAE during the screening period. 2. is a member or a family member of the investigational study staff or sponsor staff directly involved with this study.
-
has evidence or history of chronic hepatitis not caused by HCV, including but not limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune hepatitis.
-
NOTE: Subjects with history of acute non-HCV-related hepatitis, which resolved > 6 months before study entry, may be enrolled.
-
For subjects diagnosed with diabetes mellitus, documented HbA1c >8.5% (to exclude uncontrolled diabetes).
-
Has any of the following conditions:.
-
Subject with a history of gastric surgery (e.g., stapling, bypass) or subject with a history of malabsorption disorders (e.g., celiac sprue disease).
-
Any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial.
-
Has exclusionary laboratory values as listed below (see Table 5 for unit conversions of some laboratory values specified below):
-
Note: If any of the laboratory exclusion criteria below are met, the site may have the abnormal value retested one time.
Table 5: Exclusionary laboratory values:
-
Laboratory Assessment
-
hemoglobin < LLN (lower limit of normal) of laboratory reference range
-
neutrophils <1.5 x 103/μL (<1.2 x 103/μL for Blacks)
-
platelets <75 x 103/μL
-
direct bilirubin >1.5 x ULN
-
Total Bilirubin >1.6 mg/dL unless history of Gilbert's disease. (If Gilbert's disease is the proposed etiology, this must be documented in the subject's chart)
-
Serum Albumin < 3.0 g/dL (lower limit of normal) of laboratory reference range
-
creatinine clearance <50 mL/min
-
INR >1.5
-
ALT >350
-
AST >350
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Clermont-Ferrand | Clermont-Ferrand | France | 63003 |
Sponsors and Collaborators
- University Hospital, Clermont-Ferrand
- Merck Sharp & Dohme LLC
Investigators
- Principal Investigator: Armand ABERGEL, University Hospital, Clermont-Ferrand
- Principal Investigator: Isabelle FOUCHART-HUBERT, University Hospital, Angers
- Principal Investigator: Vincent DI MARTINO, Centre Hospitalier Universitaire de Besancon
- Principal Investigator: Véronique LOUSTAUD RATTI, CHU LIMOGES
- Principal Investigator: Jérôme GOURNAY, CHU Nantes
- Principal Investigator: Tarik ASSELAH, Hôpital Beaujon
- Principal Investigator: Didier SAMUEL, Hôpital Paul Brousse
- Principal Investigator: Dominique LARREY, University Hospital, Montpellier
- Principal Investigator: Sophie METIVIER, CHU Toulouse Hopital Purpan
- Principal Investigator: Christophe HEZODE, CHU Henri Mondor
- Principal Investigator: Albert TRAN, CHU Nice hopital Archet II
- Principal Investigator: François BAILLY, Hospice civils de Lyon, hopital de la croix Rousse
- Principal Investigator: Stanislas POL, AP-HP Hopital Cochin
- Principal Investigator: Valérie CANVA, CHU de Lille
Study Documents (Full-Text)
More Information
Publications
None provided.- CHU-0285
- 2016-001363-37
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Elbasvir/Grazoprevir |
|---|---|
| Arm/Group Description | Elbasvir/Grazoprevir Fixed Dose Combination: Evaluate the efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12). |
| Period Title: Overall Study | |
| STARTED | 117 |
| COMPLETED | 117 |
| NOT COMPLETED | 0 |
Baseline Characteristics
| Arm/Group Title | Elbasvir/Grazoprevir |
|---|---|
| Arm/Group Description | Elbasvir/Grazoprevir Fixed Dose Combination: Evaluate the efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12). |
| Overall Participants | 112 |
| Age (Count of Participants) | |
| <=18 years |
0
0%
|
| Between 18 and 65 years |
86
76.8%
|
| >=65 years |
26
23.2%
|
| Age (YEARS) [Mean (Standard Deviation) ] | |
| Mean (Standard Deviation) [YEARS] |
54
(13)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
77
68.8%
|
| Male |
35
31.3%
|
| Race and Ethnicity Not Collected (Count of Participants) | |
| Region of Enrollment (Count of Participants) | |
| France |
112
100%
|
Outcome Measures
| Title | Evaluation of the Efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve as Measured by the Proportion of Subjects With Sustained Viral Response 12 Weeks After Cessation of Treatment (SVR 12). |
|---|---|
| Description | Blood samples for HCV RNA determination were collected 12 weeks after cessation of treatment and analysed by local laboratories tests |
| Time Frame | at 12 weeks post-treatment |
Outcome Measure Data
| Analysis Population Description |
|---|
| 117 were enrolled. Five patients were excluded from the analysis population because they were non genotype 1b. 112 patients were analysed in modified intention to treat |
| Arm/Group Title | Elbasvir/Grazoprevir |
|---|---|
| Arm/Group Description | One group, open label study |
| Measure Participants | 112 |
| Count of Participants [Participants] |
109
97.3%
|
| Title | Evaluation of the Safety and Tolerability of EBV/GZR Treatment by Number of Patients With Treatment-related Asthenia Reported |
|---|---|
| Description | Asthenia was defined by abnormal physical weakness or lack of energy. Asthenia was monitored throughout the study and up to 24 weeks after planned end of treatment. An investigator who is a qualified physician evaluated all adverse events, causality and severity. Only grade 1 or 2 were reported. No grade 3. Grade was evaluated with table 9 of protocol. |
| Time Frame | Between the first day of treatment to 24 weeks after the end of treatment, an average of 32 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| 117 patients were included and 5 patients were excluded from the analysis because of non genotype 1b. 112 patients were analysed in modified intention to treat |
| Arm/Group Title | Patients Treated With Elbasvir / Grazoprevir |
|---|---|
| Arm/Group Description | All patients were treated by Elbasvir / Grazoprevir. Asthenia is one of the most important adverse event reported |
| Measure Participants | 112 |
| Count of Participants [Participants] |
26
23.2%
|
| Title | Evaluation of the Safety and Tolerability of EBV/GZR Treatment by Number of Patients With Treatment-related Headache Reported |
|---|---|
| Description | Headache is defined by pain felt in the cranial box. Headache was monitored throughout the study and up to 24 weeks after planned end of treatment. An investigator who is a qualified physician evaluated all adverse events, causality and severity. Only grade 1 or 2 were reported. No grade 3. grade was evaluated with table 9 of protocol. |
| Time Frame | between the first day of treatment to 24 weeks after the end of treatment, an average of 32 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| 117 patients were included and 5 patients were excluded from the analysis because of non genotype 1b. 112 patients were analysed in modified intention to treat |
| Arm/Group Title | Patients Treated With Elbasvir/Grazoprevir |
|---|---|
| Arm/Group Description | All patients were treated by Elbasvir / Grazoprevir. Headach is one of the most important adverse event reported |
| Measure Participants | 112 |
| Count of Participants [Participants] |
25
22.3%
|
| Title | Evaluation of the Safety and Tolerability of EBV/GZR Treatment by Number of Patients With Treatment-related Digestive Disorders Reported |
|---|---|
| Description | Digestive disorders is defined by an acceleration, a slowing down or a disturbance of the intestinal transit with or without pain. Digestive disorders were monitored throughout the study and up to 24 weeks after planned end of treatment. An investigator who is a qualified physician evaluated digestive disorders causality and severity. Only grade 1 or 2 were reported. No grade 3. Grade was evaluated with table 9 of protocol. |
| Time Frame | Between the first day of treatment to 24 weeks after the end of treatment, an average of 32 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| 117 patients were included and 5 patients were excluded from the analysis because of non genotype 1b. 112 patients were analysed in modified intention to treat |
| Arm/Group Title | Patients Treated With Elbasvir/Grazoprevir |
|---|---|
| Arm/Group Description | All patients were treated by Elbasvir / Grazoprevir. Digestive disorders are one of the most important adverse event reported |
| Measure Participants | 112 |
| Count of Participants [Participants] |
16
14.3%
|
| Title | Percentage of Subjects Who Attain SVR at 4 Weeks After Cessation of Treatment (SVR4) |
|---|---|
| Description | blood samples were collected at 4 weeks after cessation of treatment and HCV RNA was measured using local laboratories tests |
| Time Frame | at 4 weeks after cessation of treatment |
Outcome Measure Data
| Analysis Population Description |
|---|
| 117 patients were enrolled. 5 patients were excluded from the analysis because they were non genotype 1b. 112 patients were analysed in modified intention to treat |
| Arm/Group Title | Elbasvir/Grazoprevir |
|---|---|
| Arm/Group Description | Elbasvir/Grazoprevir Fixed Dose Combination: Evaluate the efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12). |
| Measure Participants | 112 |
| Count of Participants [Participants] |
111
99.1%
|
| Title | Percentage of Subjects Who Attain SVR 24 Weeks After Cessation of Treatment (SVR 24) |
|---|---|
| Description | blood samples were collected at 24 weeks after cessation of treatment and HCV RNA was measured using local laboratories tests |
| Time Frame | at 24 weeks after cessation of treatment |
Outcome Measure Data
| Analysis Population Description |
|---|
| 117 patients were included; 5 patients were excluded from the analysis population because they were non genotype 1b and one patient is lost to follow up 24 weeks after cessation of treatment. 111 patients were analysed in modified intention to treat |
| Arm/Group Title | Elbasvir/Grazoprevir |
|---|---|
| Arm/Group Description | Elbasvir/Grazoprevir Fixed Dose Combination: Evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12). |
| Measure Participants | 111 |
| Count of Participants [Participants] |
106
94.6%
|
| Title | Percentage of Subjects With Virologic Failure |
|---|---|
| Description | patient with HCV RNA > low limit of quantification in two different consecutive blood samples were considered as relapser |
| Time Frame | at 12 weeks after cessation of treatment |
Outcome Measure Data
| Analysis Population Description |
|---|
| 117 patients were enrolled. 5 patients were excluded from the analysis because they were non genotype 1b. 112 patients were analysed in modified intention to treat |
| Arm/Group Title | Elbasvir/Grazoprevir |
|---|---|
| Arm/Group Description | Elbasvir/Grazoprevir Fixed Dose Combination: Evaluate the efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12). |
| Measure Participants | 112 |
| Count of Participants [Participants] |
3
2.7%
|
| Title | Evaluation of the Emergence of Viral Resistance to EBV/GZR at 24 Weeks After Cessation of Treatment |
|---|---|
| Description | Patients with HCV RNA> low limit of quantification in two consecutive blood samples were considered as relapsers. |
| Time Frame | at 24 weeks after end of treatment |
Outcome Measure Data
| Analysis Population Description |
|---|
| 111 patients were analysed in modified intention to treat (5 were non genotype 1b and one was lost to follow up at week 24 after the end of treatment) |
| Arm/Group Title | Elbasvir/Grazoprevir |
|---|---|
| Arm/Group Description | Elbasvir/Grazoprevir Fixed Dose Combination: Evaluate the efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12). |
| Measure Participants | 111 |
| Count of Participants [Participants] |
5
4.5%
|
Adverse Events
| Time Frame | adverse events were collected between the first day of treatment to 24 weeks after the end of treatment, an average of 32 weeks | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Elbasvir/Grazoprevir | |
| Arm/Group Description | Elbasvir/Grazoprevir Fixed Dose Combination: Evaluate the efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12). | |
All Cause Mortality |
||
| Elbasvir/Grazoprevir | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/117 (0%) | |
Serious Adverse Events |
||
| Elbasvir/Grazoprevir | ||
| Affected / at Risk (%) | # Events | |
| Total | 3/117 (2.6%) | |
| Musculoskeletal and connective tissue disorders | ||
| FRACTURE OF ANATOMICAL NECK OF HUMERUS | 1/117 (0.9%) | 1 |
| Psychiatric disorders | ||
| MELANCHOLIA | 1/117 (0.9%) | 1 |
| ATTEMPTED SUICIDE | 1/117 (0.9%) | 1 |
Other (Not Including Serious) Adverse Events |
||
| Elbasvir/Grazoprevir | ||
| Affected / at Risk (%) | # Events | |
| Total | 69/117 (59%) | |
| Gastrointestinal disorders | ||
| DIGESTIVE DISORDERS | 19/117 (16.2%) | 19 |
| General disorders | ||
| ASTHENIA | 25/117 (21.4%) | 25 |
| HEADACHE | 25/117 (21.4%) | 25 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Armand Abergel |
|---|---|
| Organization | CHU Clermont-Ferrand |
| Phone | +33473750523 |
| aabergel@chu-clermontferrand.fr |
- CHU-0285
- 2016-001363-37